Solu-Cortef

Last Updated: 04/28/2026

Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
1 clinical trial found

    A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

    A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

    Who is this study for: Child to young adult patients with B Cell CD19-Positive Acute Lymphoblastic Leukemia
    Enrollment Status: Recruiting
    Publish Date: September 10, 2025
    Intervention Type: Procedure, Drug, Radiation, Biological
    Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
    Study Phase: Phase 2

    Summary: This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blin...

    Showing 1-1 of 1

    Last Updated: 04/28/2026